Semaglutide and tirzepatide get named in the same sentence so often that it's easy to assume one is a refined version of the other. At the level of the amino acid sequence, they aren't related that way at all. Everything below concerns research-grade material supplied for research use only — not for human or animal consumption, and not a substitute for any approved medicine.
"Mono-agonist" and "dual agonist" aren't marketing words. They describe how many receptor systems a peptide's structure was built to engage, and that decision shows up in the backbone each molecule was assembled on. If you're researching either compound, the structure is where the real distinction lives.
Here's the order: the two native hormones, the edits each molecule carries, what binding data says about receptor preference, the structural biology behind it, and the signaling behavior seen in cell culture.
Two Incretin Hormones, Two Receptors
Before comparing the molecules, you need the hormones they descend from. That's the whole fork in the road.
GLP-1 and GIP are separate signaling systems
Glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide are both incretins — gut-derived peptide hormones released in response to nutrients. They are not variations on one theme. Each is a distinct molecule acting through its own receptor, with its own structure and its own intracellular signaling profile. If the native sequences aren't familiar yet, start with our primer on the incretin peptide class and the native GLP-1 and GIP sequences.
Both native hormones share a design problem. Dipeptidyl peptidase-4 (DPP-4) clips them near the N-terminus within minutes of release, so any analogue meant to circulate for longer has to solve that first. It's why nearly every long-acting incretin analogue carries some form of structural armor at the molecule's front end.
Mono-agonist and dual agonist, defined structurally
A mono-agonist is built around one receptor as the design target. Semaglutide fits: it shares roughly 94% sequence homology with human GLP-1 and selectively activates the GLP-1 receptor. A dual agonist is one peptide chain built to engage two receptors at once. That same review frames tirzepatide as a fundamentally different pharmacological class rather than an optimized GLP-1 variant — the distinction being receptor coverage, not degree within a single receptor system.
Semaglutide: A GLP-1 Backbone With Three Deliberate Edits
Semaglutide is native GLP-1 carrying three targeted modifications. One buys enzyme resistance, one clears an acylation site, and one buys time in circulation.
Aib at position 8
The first edit swaps alanine at position 8 for 2-aminoisobutyric acid (Aib), a non-natural residue with a quaternary alpha-carbon. That substitution blocks DPP-4 cleavage at the N-terminus — the single change that moves the molecule from a minutes-long presence to a days-long one. Position 8 is the standard target for this trick across the whole GLP-1 analogue family.
Arginine at position 34
The second edit replaces native lysine at position 34 with arginine. Lysine side chains are the anchor point for fatty-acid conjugation, so removing one of the two available lysines leaves a single unambiguous attachment site. The payoff is a chemically defined product instead of a mixture of regioisomers — which matters to anything that has to pass an identity specification.
The C18 diacid on Lys26
The third edit is the longevity mechanism. A long spacer ending in an eighteen-carbon chain with a terminal carboxyl group hangs off lysine 26. That lipid tail binds serum albumin, and albumin-bound peptide is shielded from renal clearance and enzymatic attack. Reported half-life runs about seven days — 165 to 184 hours.
The numbers on the page
Semaglutide's molecular formula is C187H291N45O59, molar mass 4,113.641 g/mol. Residue numbering follows the GLP-1(7-37) convention, which is why the first six proglucagon-derived residues are absent from the sequence — a nomenclature detail that trips up almost everyone comparing position numbers across papers.
Tirzepatide: A GIP Backbone Engineered to Speak GLP-1
Tirzepatide started from the other hormone, and the design brief ran in the direction most people assume backwards: GLP-1 activity was engineered into the GIP sequence, not the reverse.